CNS Pharmaceuticals Inc
$ 2.97
-5.11%
24 Feb - close price
- Market Cap 1,798,400 USD
- Current Price $ 2.97
- High / Low $ 3.12 / 2.95
- Stock P/E N/A
- Book Value 17.25
- EPS 776.03
- Next Earning Report 2026-04-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.86 %
- ROE -1.97 %
- 52 Week High 55.20
- 52 Week Low 2.95
About
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central nervous system tumors. The company is headquartered in Houston, Texas.
Analyst Target Price
$20.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-14 | 2025-08-13 | 2025-04-30 | 2025-03-31 | 2024-11-13 | 2024-08-14 | 2024-05-15 | 2024-03-14 | 2023-11-13 | 2023-08-14 | 2023-05-15 | 2023-03-31 |
| Reported EPS | -5.76 | -6.42 | -2.2471 | -37.33 | -0.2527 | -6.7192 | -0.4068 | -28622.9609 | -2.7 | -1.0371 | -2.5869 | -3.8211 |
| Estimated EPS | -0.63 | -9.6 | -2 | -7.33 | -0.1 | None | None | None | -2.4 | None | None | -2.4 |
| Surprise | -5.13 | 3.18 | -0.2471 | -30 | -0.1527 | 0 | 0 | 0 | -0.3 | 0 | 0 | -1.4211 |
| Surprise Percentage | -814.2857% | 33.125% | -12.355% | -409.2769% | -152.7% | None% | None% | None% | -12.5% | None% | None% | -59.2125% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-04-07 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CNSP
2026-02-18 09:57:37
CNS Pharmaceuticals (NASDAQ:CNSP) has appointed Steven O’Loughlin as CFO, Eric Faulkner as CTO, and Dylan Wenke as CBO, effective March 2, 2026. This strategic move follows the recent appointment of Rami Levin as President and CEO and aims to transform the micro-cap biopharmaceutical company amidst stock challenges. The company, which develops treatments for brain and central nervous system cancers, is focusing on "Patients First, Pipeline Enrichment and Optimization, and Disciplined Value Creation."
2026-02-18 09:27:27
CNS Pharmaceuticals has appointed Steven O’Loughlin as CFO, Eric Faulkner as CTO, and Dylan Wenke as CBO, effective March 2nd. This move is part of a strategic transformation initiative led by newly appointed President and CEO Rami Levin, aimed at revitalizing the micro-cap biopharmaceutical company. The company, which is developing TPI 287 for brain and central nervous system cancers, seeks to become a more "strategic, forward-looking, execution-driven biotechnology company" through these changes.
2026-02-17 14:28:22
CNS Pharmaceuticals announced key appointments to its executive team, effective March 2, 2026, under the leadership of newly appointed President and CEO Rami Levin. Steven O’Loughlin has been named CFO, Eric Faulkner as CTO, and Dylan Wenke as CBO. These strategic hires aim to drive the company's evolution, leveraging the new executives' extensive experience in the pharmaceutical and biotech sectors.
2026-02-17 14:28:22
CNS Pharmaceuticals has appointed Steve O’Loughlin as its new Chief Financial Officer, effective March 2, 2026, bringing extensive biotech finance experience. Current CFO Christopher Downs will transition to Senior Vice President – Finance on the same date, ensuring continuity. The company aims to strengthen its financial leadership and strategy to support anticipated growth, although TipRanks' AI Analyst "Spark" rates CNSP as Neutral due to weak financial performance despite moderate technical support.
2026-02-17 14:28:22
CNS Pharmaceuticals (NASDAQ:CNSP) has appointed Steven O’Loughlin as CFO, Eric Faulkner as CTO, and Dylan Wenke as CBO, effective March 2nd, as part of a strategic transformation initiative. These appointments follow the recent hiring of Rami Levin as President and CEO and aim to enhance the company's focus on developing treatments for brain and central nervous system cancers, particularly its anti-cancer drug candidate, TPI 287. The company's stock is currently trading near its 52-week low amidst these changes.
2026-02-17 13:28:22
CNS Pharmaceuticals (NASDAQ:CNSP) has appointed Steven O'Loughlin as CFO, Eric Faulkner as CTO, and Dylan Wenke as CBO, effective March 2, 2026. These strategic hires, made by new President & CEO Rami Levin, are part of a company-wide transformation focusing on pipeline optimization, capital allocation, and execution for treatments of brain and central nervous system cancers. The new executive team brings extensive experience in biotech, finance, and business development to drive the company's growth and value creation.
